MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J.M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'Hearn, S., Gaber, A., Gorman, I., Paleos, C., Gorham, L., Yazar-Klosinski, B.B., Emerson, A., Doblin, R. (2021) Nature Medicine , 27(6) , 1025-1033
Zusammenfassung
This phase 3 randomized, double-blind, placebo-controlled trial evaluated MDMA-assisted therapy for severe PTSD. After three sessions, 67% of participants no longer met diagnostic criteria for PTSD, compared to 32% in the placebo group.
Schlüsselwörter
MDMAPTSDphase 3clinical trialpsychedelic therapy
Klinische Forschung